Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 70.1% in June

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 6,105 shares, a drop of 70.1% from the June 15th total of 20,390 shares. Based on an average trading volume of 64,461 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Stock Performance

Shares of Matinas Biopharma stock traded up $0.13 on Friday, hitting $0.76. 1,681,787 shares of the company’s stock were exchanged, compared to its average volume of 126,202. Matinas Biopharma has a 1 year low of $0.48 and a 1 year high of $3.09. The company has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $0.63. The stock has a market capitalization of $4.84 million, a PE ratio of -0.38 and a beta of 1.71.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.